Thalidomide in Thalassemia Intermedia

Investigating the Effects of Thalidomide on Hemoglobin Levels in Patients with Thalassemia Intermedia: A Clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180603039959N5

Enrollment

Registered

2025-02-15

Start date

2025-02-28

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thalassemia intermedia. Beta thalassemia

Interventions

Intervention group:.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Visiting the Baghaei 2 Medical Center and having a medical record there Dependency on blood transfusions Lack of a favorable response to hydroxyurea treatment Age over 18 years Baseline hemoglobin level of less than 10 Signing the informed consent form

Exclusion criteria

Exclusion criteria: History of hypersensitivity reaction to thalidomide Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Hemoglobin. Timepoint: Before starting the medication and at the end of 8 weeks. Method of measurement: Hemoglobin level will be measured using a complete blood count (CBC) test with a hematology analyzer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDaryush Purrahman

Ahvaz University of Medical Sciences

daryushpurrahman@gmail.com+98 61 3375 0410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026